晚期卵巢癌患者原发性肿瘤和腹膜转移灶中血管内皮生长因子（VEGF）的表达

Vascular endothelial growth factor (VEGF) expression in primary tumors and peritoneal metastases from patients with advanced ovarian carcinoma.

作者信息

Gadducci Angiolo, Viacava Paolo, Cosio Stefania, Cecchetti Denise, Fanelli Giovanni, Fanucchi Antonio, Teti Giancarlo, Genazzani Andrea Riccardo

机构信息

Department of Procreative Medicine, Division of Gynecology and Obstetrics, University of Pisa, Via Roma 67, 56127 Pisa, Italy.

出版信息

Anticancer Res. 2003 May-Jun;23(3C):3001-8.

PMID:12926153

Abstract

BACKGROUND

Several experimental and clinical data suggest that vascular endothelial growth factor (VEGF) is involved in ovarian carcinogenesis. However, there are no conclusive data about the prognostic value of tissue VEGF expression in this malignancy. The aim of the present investigation was to compare VEGF immunostaining in primary tumors and peritoneal metastases from patients with advanced ovarian carcinoma and to assess whether this parameter has a predictive or prognostic relevance.

MATERIALS AND METHODS

The investigation was conducted on 45 patients who underwent initial surgery followed by platinum-based or paclitaxel/platinum-based chemotherapy for advanced ovarian carcinoma. Both primary tumors and peritoneal metastases were immunohistochemically analyzed for VEGF expression. Intense staining score was assigned if more than 75% of the cells stained positive.

RESULTS

Intense VEGF immunostaining was detected in 14 and 36 (31.1% versus 80.0%, p < 0.0001), respectively, of primary tumors and peritoneal metastases. Twenty-six (57.8%) patients showed an increased VEGF immunostaining in metastatic lesions compared with primary tumors. VEGF immunostaining in primary tumors, VEGF immunostaining in peritoneal metastases and change in VEGF immunostaining from the primary tumor to peritoneal metastatic lesion were related neither to the response to chemotherapy nor to progression-free survival.

CONCLUSION

In patients with advanced ovarian carcinoma, intense VEGF immunostaining was more often detected in peritoneal metastases than in primary tumors. VEGF immunostaining in primary as well as in metastatic lesions correlated neither with the response to chemotherapy nor with the clinical outcome. Therefore the immunohistochemical detection of VEGF in tissue samples collected during primary surgery failed to have a predictive or prognostic relevance for patients with advanced ovarian carcinoma.

摘要

背景

多项实验和临床数据表明血管内皮生长因子（VEGF）参与卵巢癌的发生发展。然而，关于该恶性肿瘤中组织VEGF表达的预后价值尚无确凿数据。本研究的目的是比较晚期卵巢癌患者原发肿瘤和腹膜转移灶中的VEGF免疫染色情况，并评估该参数是否具有预测或预后相关性。

材料与方法

对45例接受初始手术，随后接受铂类或紫杉醇/铂类化疗的晚期卵巢癌患者进行了研究。对原发肿瘤和腹膜转移灶均进行VEGF表达的免疫组化分析。如果超过75%的细胞染色呈阳性，则给予强染色评分。

结果

原发肿瘤和腹膜转移灶中分别有14例（31.1%）和36例（80.0%）检测到强VEGF免疫染色（p<0.0001）。26例（57.8%）患者的转移灶中VEGF免疫染色较原发肿瘤增加。原发肿瘤中的VEGF免疫染色、腹膜转移灶中的VEGF免疫染色以及从原发肿瘤到腹膜转移灶的VEGF免疫染色变化均与化疗反应和无进展生存期无关。